Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
US Open: Nasdaq surges as semiconductor stocks improve sentiments on Wall Street
🚩Avid Budget meme stock sinks as panic ended the 600% surge
Market Wrap: Indices try to recover on US-Iran negotiations hopes 🇪🇺 SAP surges 6% after earnings 📈
Intel: AI drives results, and CPUs may be the next stage of the revolution